|Mr. John P. Walker||Chairman, CEO & Pres||413.27k||N/A||1949|
|Dr. Donald J. Kellerman||VP of Clinical Devel. & Medical Affairs||426.69k||N/A||1955|
|Mr. Greg Kitchener||Chief Financial Officer||N/A||N/A||1971|
|Ms. Hayley Lewis||Sr. VP of Operations||N/A||N/A||1976|
|Jeffrey L. Quillen||Sec.||N/A||N/A||N/A|
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its lead product candidate is M207, a proprietary formulation of zolmitriptan used for the treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California.
Zosano Pharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.